Conference Coverage

Colchicine before PCI for acute MI fails to improve major outcomes


 

FROM CRT 2021

Timing might be the issue

However, even if colchicine has a potential benefit in this setting, timing might be a major obstacle, according to Binata Shah, MD, associate director of research for the Cardiac Catheterization Laboratory at New York University.

Dr. Binita Shah, New York University

Dr. Binita Shah

“We have learned from our rheumatology colleagues that peak plasma levels of colchicine are not achieved for at least 1 hour after the full loading dose,” Dr. Shah said. “With us moving so quickly in a primary PCI setting, it is hard to imagine that colchicine would have had time to really kick in and exert its anti-inflammatory effect.”

Indeed, the problem might be worse than reaching the peak plasma level.

“Even though peak plasma levels occur as early as 1 hour after a full loading dose, we see that it takes about 24 hours to really see the effects translate downstream into more systemic inflammatory markers such as CRP and interleukin-6,” she added. If lowering these signals of inflammation is predictive of benefit, than this might be the biggest obstacle to benefit from colchicine in an urgent treatment setting.

Dr. Jenab and Dr. Shah reported no potential conflicts of interest.

Pages

Recommended Reading

Dapagliflozin’s CKD performance sends heart failure messages
Federal Practitioner
Benefit of rivaroxaban after limb revascularization greatest in those with comorbid CAD
Federal Practitioner
NACMI: Clear benefit with PCI in STEMI COVID-19 patients
Federal Practitioner
Valvular disease and COVID-19 are a deadly mix; don’t delay intervention
Federal Practitioner
Higher serum omega-3 tied to better outcome after STEMI
Federal Practitioner
New-onset AFib common but unrecognized in the month after cardiac surgery
Federal Practitioner
Full-dose anticoagulation reduces need for life support in COVID-19
Federal Practitioner
Newer iPhones disable implanted defibrillators
Federal Practitioner
Microthrombi, necrosis seen in COVID-19 hearts on autopsy
Federal Practitioner
DOACs offered after heart valve surgery despite absence of data
Federal Practitioner